Statistics

Total Visits

Views
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study27

Select a period of time:

Number of views in the range

Views
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study20

Views

Views
January 20251
February 20250
March 202515
April 20253
May 20250
June 20251
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States2
Hong Kong2
Spain1
 

Top cities views

Views
Hong Kong2
Council Bluffs1